3,934,608 CONMED Corporation $CNMD Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. cut its position in CONMED Corporation (NYSE:CNMD – Free Report) by 99.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 31,700 shares of the company’s stock after selling 3,934,608 shares during the quarter. Jefferies Financial Group Inc.’s holdings in CONMED were worth $1,465,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in CONMED in the 2nd quarter valued at $157,783,000. Dimensional Fund Advisors LP increased its position in CONMED by 6.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,392,920 shares of the company’s stock valued at $49,250,000 after acquiring an additional 80,116 shares in the last quarter. Bank of America Corp DE bought a new position in shares of CONMED in the second quarter worth about $43,904,000. Allspring Global Investments Holdings LLC raised its stake in shares of CONMED by 39.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 582,733 shares of the company’s stock worth $20,705,000 after acquiring an additional 166,301 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY acquired a new position in shares of CONMED during the second quarter worth approximately $17,617,000.

CONMED Trading Up 0.1%

CNMD opened at $50.63 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.49 and a quick ratio of 0.70. The company has a market cap of $1.51 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The firm has a 50 day simple moving average of $47.14 and a 200 day simple moving average of $41.92. CONMED Corporation has a fifty-two week low of $31.44 and a fifty-two week high of $54.80.

CONMED (NYSE:CNMD – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. CONMED had a net margin of 5.36% and a return on equity of 13.93%. The firm had revenue of $335.56 million for the quarter, compared to analysts’ expectations of $336.28 million. During the same period last year, the firm earned $1.08 earnings per share. The business’s revenue for the quarter was down .7% on a year-over-year basis. On average, sell-side analysts anticipate that CONMED Corporation will post 4.58 earnings per share for the current year.

Analyst Ratings Changes

CNMD has been the subject of a number of research reports. JPMorgan Chase & Co. raised their price target on shares of CONMED from $45.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, October 29th. Piper Sandler reiterated a “neutral” rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a research report on Thursday, July 30th. Wells Fargo & Company lifted their target price on CONMED from $46.00 to $49.00 and gave the company an “equal weight” rating in a research note on Thursday, October 29th. Zacks Research upgraded CONMED from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded CONMED from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Seven research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $44.00.

View Our Latest Report on CNMD

CONMED Profile

(Free Report)

CONMED Corporation is a medical technology company that develops and markets devices and equipment for orthopedic and general surgery. Its products support minimally invasive procedures and include arthroscopy systems, powered surgical instruments, electrosurgical equipment, and endoscopic technologies. The company was founded in 1970 and serves hospitals, surgery centers, and other healthcare providers. Its products are sold in the United States and internationally.

Further Reading

Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD – Free Report).

Institutional Ownership by Quarter for CONMED (NYSE:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.